Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010-present).
Fiche publication
Date publication
décembre 2020
Journal
Expert opinion on therapeutic patents
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen, Pr LIRUSSI Frédéric
Tous les auteurs :
Hu S, Hui Z, Lirussi F, Garrido C, Ye XY, Xie T
Lien Pubmed
Résumé
DNA-dependent protein kinase (DNA-PK) plays a crucial role in the repair of DSBs via non-homologous end joining (NHEJ). Several DNA-PK inhibitors are being investigated for potential anticancer treatment in clinical trials.
Mots clés
DNA damage response (DDR), DNA double strand breaks (DSBs), DNA-PK, cancer therapy, inhibitor, patent review
Référence
Expert Opin Ther Pat. 2020 Dec 21;: